PerkinElmer, Inc. (0KHE.L)
| Previous close | 136.82 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 15.129B |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | 21.12 |
| EPS (TTM) | 6.50 |
| Earnings date | 30 Jan 2023 - 03 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
PerkinElmer's (PKI) New Viral Vector Assays to Boost Workflows
PerkinElmer's (PKI) latest launch is expected to help researchers expand options to measure viral titers, unlike ELISA and other wash-based systems.
- Business Wire
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
WALTHAM, Mass., November 21, 2022--PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on gene therapies for a variety of serious diseases. The high-throughput viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer.
- Simply Wall St.
PerkinElmer Third Quarter 2022 Earnings: EPS Misses Expectations
PerkinElmer ( NYSE:PKI ) Third Quarter 2022 Results Key Financial Results Revenue: US$711.8m (down 17% from 3Q 2021...
